High-flow nasal cannula oxygen therapy for asthma exacerbation

Aiko Honda; Yoshitaka Watanabe; Yoshifusa Abe; Sojiro Kusumoto; Takeshi Hasegawa; Hisashi Noma; Erika Ota; Takanori Imai; Noyuri Yamaji; Edward Barroga

doi:10.1002/14651858.CD016205

High-flow nasal cannula oxygen therapy for asthma exacerbation

Cochrane Database Syst Rev. 2025 Dec 9;12(12):CD016205. doi: 10.1002/14651858.CD016205.

Authors

Aiko Honda^{1

2}, Yoshitaka Watanabe³, Yoshifusa Abe^{2

4}, Sojiro Kusumoto⁵, Takeshi Hasegawa^{2

6

7}, Hisashi Noma^{2

8}, Erika Ota^{2

9}, Takanori Imai¹, Noyuri Yamaji^{2

10}, Edward Barroga¹¹

Affiliations

¹ Department of Pediatrics, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
² Institute of Clinical Epidemiology (iCE), Showa Medical University, Tokyo, Japan.
³ Children's Medical Center, Showa Medical University Northern Yokohama Hospital, Kanagawa, Japan.
⁴ Children's Medical Center, Showa Medical University Koto Toyosu Hospital, Tokyo, Japan.
⁵ Department of Medicine, Division of Respiratory Medicine and Allergology, Showa Medical University Hospital, Tokyo, Japan.
⁶ Department of Hygiene, Public Health, and Preventive Medicine, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
⁷ Department of Nephrology, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
⁸ Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tokyo, Japan.
⁹ Global Health Nursing, St.Luke's International University, Tokyo, Japan.
¹⁰ Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
¹¹ Medical English Education Center, Showa Medical University School of Medicine, Tokyo, Japan.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the clinical effectiveness and safety of high-flow nasal cannula (HFNC) oxygen therapy compared with conventional oxygen therapy for the management of asthma exacerbations in children and adults. We will also explore potential equity implications, including differences in access to and outcomes of HFNC oxygen therapy across diverse healthcare settings and populations.

MeSH terms

Adult
Asthma* / therapy
Cannula
Child
Disease Progression
Humans
Oxygen Inhalation Therapy* / adverse effects
Oxygen Inhalation Therapy* / instrumentation
Oxygen Inhalation Therapy* / methods
Randomized Controlled Trials as Topic